EZH2 noncanonically binds cMyc and p300 through a cryptic transactivation domain to mediate gene activation and promote oncogenesis-Reference-Cited by-同舟云学术

EZH2 noncanonically binds cMyc and p300 through a cryptic transactivation domain to mediate gene activation and promote oncogenesis

Published:2022-02-24 Issue:3 Volume:24 Page:384-399
ISSN:1465-7392
Container-title:Nature Cell Biology
language:en
Short-container-title:Nat Cell Biol

Author:

Wang Jun,Yu Xufen,Gong Weida,Liu Xijuan,Park Kwang-Su,Ma Anqi,Tsai Yi-Hsuan^ORCID,Shen Yudao,Onikubo Takashi,Pi Wen-Chieh,Allison David F.,Liu Jing,Chen Wei-Yi,Cai Ling,Roeder Robert G.,Jin Jian^ORCID,Wang Gang Greg^ORCID

Funder

U.S. Department of Health & Human Services | NIH | National Cancer Institute

Publisher

Springer Science and Business Media LLC

Subject

Cell Biology

Link

https://www.nature.com/articles/s41556-022-00850-x.pdf

Reference92 articles.

1. Yu, J. R., Lee, C. H., Oksuz, O., Stafford, J. M. & Reinberg, D. PRC2 is high maintenance. Genes Dev. 33, 903–935 (2019).

2. Guo, Y., Zhao, S. & Wang, G. G. Polycomb gene silencing mechanisms: PRC2 chromatin targeting, H3K27me3 ‘readout’, and phase separation-based compaction. Trends Genet. 37, 547–565 (2021).

3. Kim, K. H. & Roberts, C. W. Targeting EZH2 in cancer. Nat. Med. 22, 128–134 (2016).

4. Xu, B., Konze, K. D., Jin, J. & Wang, G. G. Targeting EZH2 and PRC2 dependence as novel anticancer therapy. Exp. Hematol. 43, 698–712 (2015).

5. Wang, X. et al. Clinical and prognostic relevance of EZH2 in breast cancer: a meta-analysis. Biomed. Pharmacother. 75, 218–225 (2015).

Cited by 108 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Amphiphilic Affibody-PROTAC conjugate Self-Assembled nanoagents for targeted cancer therapy;Chemical Engineering Journal;2024-09

2. Lineage-specific canonical and non-canonical activity of EZH2 in advanced prostate cancer subtypes;Nature Communications;2024-08-08

3. EZH2 PROTACs target EZH2- and FOXM1-associated oncogenic nodes, suppressing breast cancer cell growth;Oncogene;2024-08-07

4. Exploration of Hydrazide-Based HDAC8 PROTACs for the Treatment of Hematological Malignancies and Solid Tumors;Journal of Medicinal Chemistry;2024-08-01

5. Anlotinib potentiates anti‐PD1 immunotherapy via transferrin receptor‐dependent CD8⁺ T‐cell infiltration in hepatocellular carcinoma;Clinical and Translational Medicine;2024-08